

GenesisCare Foundation Compassionate Access Programme

What outcome data will be collected?

The primary purpose of the GenesisCare Foundation **Compassionate Access Programme** is to make precision radiotherapy available during the COVID-19 pandemic, and its aftermath. Patients are under no obligation whatsoever to participate in the collection of PROMs, and referrers are under no obligation to provide follow up data.

The secondary purpose, however, is to generate a body of data that will inform the development of clinical trials aimed at establishing a definitive role for SABR in the management of pancreatic cancer. As such, we aspire to collect the following data on all patients treated within the Programme.

Patient-reported quality of life using the EORTC QLQ-C30 and QLQ-PAN26 tools at baseline, four weeks, three months, six months, 12 months and 18 months

- Clinician-reported toxicity according to CTCAE version 4.0 criteria
- Six-month and 12-month local control, as defined on local imaging
- Overall progression-free survival, as defined on local imaging
- Overall survival at 18 months
- Investigational imaging biomarkers of local control (details to be confirmed)